SCHEMBL17217745

SCHEMBL17217745

Fc1cccc([C]=NOCc2ccc(-c3ccccc3)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TAAR1 Q96RJ0 4/20 0.43
▸ GPR34 Q9UPC5 1/20 0.39
▸ AGXT P21549 3/20 0.39
▸ IDO1 P14902 2/20 0.39
▸ SRC P12931 1/20 0.39
▸ CYP17A1 P05093 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP11B1 P15538 1/20 0.38
▸ CYP11B2 P19099 1/20 0.38
▸ ESR2 Q92731 1/20 0.38
▸ GSTP1 P09211 1/20 0.38
▸ MGLL Q99685 1/20 0.36
▸ HCAR2 Q8TDS4 1/20 0.36
▸ CETP P11597 1/20 0.36
▸ MAOB P27338 1/20 0.35
▸ NPC1 O15118 1/20 0.35
▸ RAB9A P51151 1/20 0.35
▸ NAAA Q02083 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ FFAR1 O14842 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17217742 1.00 TAAR1 (0.43) TAAR1GPR34AGXTIDO1SRC
SCHEMBL17219752 0.91 IDO1 (0.41) TAAR1AGXTIDO1HCAR2MAOB
SCHEMBL17219753 0.91 IDO1 (0.41) TAAR1AGXTIDO1HCAR2MAOB
SCHEMBL17217141 0.90 AGXT (0.45) TAAR1GPR34AGXTIDO1ESR2
SCHEMBL17217139 0.90 AGXT (0.45) TAAR1GPR34AGXTIDO1ESR2
SCHEMBL17218127 0.88 MAOB (0.39) AGXTIDO1MAOBSMN1; SMN2
SCHEMBL17218129 0.88 MAOB (0.39) AGXTIDO1MAOBSMN1; SMN2
SCHEMBL17217275 0.85 IDO1 (0.48) TAAR1AGXTIDO1GSTP1NPC1
SCHEMBL17217277 0.85 IDO1 (0.48) TAAR1AGXTIDO1GSTP1NPC1
SCHEMBL17218113 0.84 L3MBTL1 (0.38) AGXTIDO1CYP3A4MAOBSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2940012-B1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF SUMITOMO CHEMICAL CO (JP) 2019-01-30 — — EP disclosed
US-9560850-B2 Tetrazolinone compound and use thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2017-02-07 — — US disclosed
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2015-11-26 — — US disclosed
EP-2940012-A1 TETRAZOLINONE COMPOUND AND APPLICATIONS THEREOF Sumitomo Chemical Company Limited (JP) 2015-11-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150336908-A1 TETRAZOLINONE COMPOUND AND USE THEREOF RTN3, CYP51A1, TCOF1 TAAR1 21/4885GPR34 3219/4885AGXT 1423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback